Activist Investor Braeden Lichti and Northstrive Fund II LP Fully Exit Bluejay Diagnostics Stake
BJDX has more than doubled off its 52-week low of $1.623 on elevated volume (59× avg).
Summary
Activist investor Braeden Lichti and Northstrive Fund II LP have fully divested their stake in Bluejay Diagnostics, marking a complete exit from the company.
Key Events · Ownership and Investor Activity · BJDX
-
Activist Investor Exit
Braeden Lichti and Northstrive Fund II LP have sold all their previously owned shares of Bluejay Diagnostics common stock.
-
Cessation of Beneficial Ownership
The reporting persons no longer beneficially own any shares of the Issuer's common stock, ceasing to be a greater than five percent owner as of June 2, 2026.
-
Final Amendment
This Schedule 13D/A filing is the final amendment and constitutes an exit filing for the reporting persons.
-
Context of Prior Activism
The reporting persons had previously filed a Schedule 13D on March 11, 2026, proposing a strategic biotechnology acquisition for the company.
Analysis · BJDX · Industrial Applications And Services
Activist investor Braeden Lichti and Northstrive Fund II LP, who previously proposed a strategic acquisition for Bluejay Diagnostics, have now sold their entire stake. This complete divestment removes a potential strategic partner or acquirer at a critical time, especially as the company faces significant financial challenges, including a 'going concern' warning and efforts to avoid Nasdaq delisting through a reverse stock split. The exit signals a loss of confidence from a previously engaged shareholder.
At the time of this filing, BJDX was trading at $4.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.62 to $16.68. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.